Dr. Amélie Bonnefond
NAME: Bonnefond Amélie
ORCID: 0000-0001-9976-3005 // Web of Science ResearcherID: O-2784-2017
POSITION TITLE: Director of Research (DR1, Inserm)
EDUCATION/TRAINING
| INSTITUTION AND LOCATION | DEGREE | Completion Date | FIELD OF STUDY |
| SupAgro, Montpellier, France | Engineering Master Degree | 2007 | Agriculture, Food and Environment |
| University of Montpellier, Montpellier, France | MSc | 2007 | Human Biology and Health |
| University of Lille, Lille, France | PhD | 2010 | Human Genetics |
| University of Lille, Lille, France | HDR | 2014 | Human Genetics |
POSITIONS
2024–now Director of Research at Inserm (DR1) / Leader of an Inserm Team (including 17 scientists and university hospital clinicians; 9 post-docs; 10 PhD students) Inserm/CNRS UMR1283/8199, Lille University, Lille, France
2015–now Honorary Research Scientist Department of Metabolism, Imperial College London
2012–now Scientific Director of the Lille Genomic Platform ‘LIGAN-personalized medicine’ 30 Engineers, Research Associates and Assistants Inserm/CNRS UMR1283/8199
2020–2023 Director of Research at Inserm (DR2) / Leader of an Inserm Team (including 17 scientists and university hospital clinicians; 9 post-docs; 10 PhD students) Inserm/CNRS UMR1283/8199, Lille University, Lille, France
2014–2019 Senior Research Scientist at Inserm (CR1) CNRS UMR8199, Lille University, Lille
2012–2014 Postdoctoral researcher CNRS UMR8199 (headed by Prof Philippe Froguel)
2011–2012 Visiting postdoctoral researcher INSERM unit headed by Prof Michel Marre, Paris 7 University, Paris, France
2011–2012 Postdoctoral fellow INSERM unit headed by Dr Sophie Visvikis, Lorraine University, France
CONTRIBUTIONS TO SCIENCE
Dissection of the genetic etiologies of type 2 diabetes (T2D) / obesity, through integrative studies combining human genetics and functional studies, in order to progress into pathophysiology (with drug targets discovery) and to better stratify patients towards precision medicine.
I have published more than 203 PubMed indexed papers. Among them:
- 84 articles were signed as (co-)first, (co-)corresponding and/or (co-)last author (including papers in Nature, Nature Medicine, Nature Metabolism, Nature Genetics, Lancet Diabetes Endocrinology, Journal of Clinical Investigation)
- H-index of 67 (Google Scholar); Complete List of Published Work in MyBibliography: https://pubmed.ncbi.nlm.nih.gov/?term=(Bonnefond%20Amelie)%20OR%20(Bonnefond%20A[Author]%20AND%20Roussel[Author])%20OR%20(Bonnefond%20A[Author]%20AND%20Froguel[Author])%20OR%20(Bonnefond%20A[Author]%20AND%20Vaxillaire[Author])%20OR%20(Bonnefond%20A[Author]%20AND%20Siest[Author])%20OR%20(Bonnefond%20A[Author]%20AND%20Moreaux%20J[Author])
HONORS
2022 Consolidator Grant Award from the European Research Council (ERC-LS4; Opio)
2021 Minkowski Prize from the European Association for the Study of Diabetes (EASD)
2019 Upgrade my NGSAward from PerkinElmer (Sciclone NGS Workstation; cost: k€ 200)
2018 Auguste Loubatières Prize from the French-speaking Association for Diabetes (SFD)
2016 Starting Grant Award from the European Research Council (ERC-LS7; Reg-Seq)
2013 Young Investigator Travel Grant Award from the American Diabetes Association (ADA)
2012 Rising Star Award from the European Association for the Study of Diabetes (EASD)
OTHERS
– Organisation of scientific meetings (member of the program committee): American Society of Human Genetics (ASHG) and French Association for Diabetes (SFD)
– Associate Editor for Diabetologia